Atrophy

Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD

Retrieved on: 
Thursday, March 7, 2024

The AAV-SLB101 capsid has been shown in preclinical studies to have enhanced biodistribution and improved expression in muscle cells.

Key Points: 
  • The AAV-SLB101 capsid has been shown in preclinical studies to have enhanced biodistribution and improved expression in muscle cells.
  • Under the terms of the agreement, Solid granted Armatus a non-exclusive worldwide license to utilize AAV-SLB101 for treatment of FSHD and will provide Armatus AAV-SLB101 plasmid material, preclinical data characterizing AAV-SLB101, and manufacturing and regulatory know-how to enable development.
  • Armatus will be responsible for the development and commercialization of licensed products incorporating AAV-SLB101.
  • With this license in place, we are eager to advance our optimized ARM-201 construct as the lead candidate toward clinical evaluation.”

Elixirgen Therapeutics Presents Preclinical Data with Bobcat mRNATM Technology in Duchenne Muscular Dystrophy at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Retrieved on: 
Monday, March 4, 2024

BALTIMORE, March 04, 2024 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its mRNA platforms, today presented preclinical data on its proprietary Bobcat mRNATM technology in a poster presentation at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference taking place March 3-6, 2024, in Orlando, Florida. Bobcat mRNATM is designed to deliver large protein payloads (over 13 kb), and results show that a Bobcat mRNATM encoding a full-length dystrophin protein can restore muscular function in a mouse model for Duchenne muscular dystrophy (DMD).

Key Points: 
  • Bobcat mRNATM is designed to deliver large protein payloads (over 13 kb), and results show that a Bobcat mRNATM encoding a full-length dystrophin protein can restore muscular function in a mouse model for Duchenne muscular dystrophy (DMD).
  • “We’re excited to be presenting these promising data on our novel Bobcat mRNATM technology.
  • “Our Bobcat mRNATM full-length dystrophin approach may be complementary to others currently approved or in development, or may even mitigate some of their issues.
  • We’re pleased to add the Bobcat mRNATM technology to our pipeline of RNA technologies and look forward to sharing updates in the months ahead.”

RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy

Retrieved on: 
Thursday, February 22, 2024

PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“ RetinalGeniX ” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company's System And Method For Visualization Of Ocular Anatomy.

Key Points: 
  • PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“ RetinalGeniX ” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company's System And Method For Visualization Of Ocular Anatomy.
  • The present invention relates to systems and methods for visualizing eye anatomy for diagnostic and therapeutic purposes.
  • Furthermore, it allows for the detection and analysis of various conditions of the eye, such as, hydration, innervations, inflammation, circulation, nerve conduction, etc.
  • Some of the best-studied ocular conformational diseases include cataracts in the lens and retinitis pigmentosa in the retina.

BioAdaptives, Inc. Announces NaturaComplete™, an All-In-One Supplement to Optimize Its AI-Based FYO Obesity Management System

Retrieved on: 
Thursday, February 22, 2024

Some dietary methods and the use of certain obesity drugs, like semaglutide, are reported to have unwanted side effects including gastro-intestinal problems like delayed gastric emptying, muscle mass decrease and hair loss.

Key Points: 
  • Some dietary methods and the use of certain obesity drugs, like semaglutide, are reported to have unwanted side effects including gastro-intestinal problems like delayed gastric emptying, muscle mass decrease and hair loss.
  • The ingredients in NaturaComplete™ help to increase the amount of bioavailable nutrients, provide more protein building blocks, stimulate the body’s Primitive cells needed for immune defense and healing, and promote better quality of skin, hair, and nails.
  • This concept has been demonstrated in the highly popular and convenient, One-Stop, Equine All-In-One products, developed by BioAdaptives and shown to have rejuvenating, anti-aging, and performance effects in horses.
  • NaturaComplete™ may be used in conjunction with the AI supported FYO Body Composition smartphone App and can be taken as a meal replacement or as a complementary, additional supplement with any diet.”

RetinAI Discovery® platform and AI tools launched to improve decision workflows, referrals and patient management in Clinics for Ophthalmologists and Optometrists

Retrieved on: 
Tuesday, February 20, 2024

US (“RetinAI”), a leader in developing software solutions for image processing and artificial intelligence (AI) in Ophthalmology, has launched RetinAI Discovery® for Clinics ('Discovery'), with two product versions to address the needs of Ophthalmologists and Optometrists.

Key Points: 
  • US (“RetinAI”), a leader in developing software solutions for image processing and artificial intelligence (AI) in Ophthalmology, has launched RetinAI Discovery® for Clinics ('Discovery'), with two product versions to address the needs of Ophthalmologists and Optometrists.
  • Discovery for Clinics and its expert-level AI models have been designed to accelerate and enhance clinical decision workflows, teleophthalmology management, referral decisions and patient management generating data efficiencies and enhancing decisions for clinics.
  • The vendor neutral and multi-modality platform harmonizes, aggregates, and connects large datasets on a single, cloud-based repository for data.
  • The data is then automatically analyzed with RetinAI’s CE-marked and Research Use Only (RUO) AI algorithms for accelerated and AI-biomarker based treatment decisions.

Cognito Therapeutics OVERTURE Clinical Trial in Alzheimer's Disease Published in Frontiers in Neurology

Retrieved on: 
Wednesday, March 6, 2024

Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today the publication of the OVERTURE study results in Frontiers in Neurology .

Key Points: 
  • Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today the publication of the OVERTURE study results in Frontiers in Neurology .
  • The OVERTURE clinical trial was a randomized, double-blind, sham-controlled clinical trial conducted over a six-month period at 5 US clinical trial sites, involving participants with mild to moderate AD.
  • Participants were randomly assigned 2:1 to receive self-administered daily, one-hour Spectris therapy designed to evoke EEG-verified gamma oscillations or sham treatment.
  • “Publication of OVERTURE clinical trial results is an important step in our commitment to develop our technology-based therapeutic intervention in Alzheimer’s disease,” said Ralph Kern, M.D., MHSc, Chief Medical Officer of Cognito Therapeutics.

Springbok Analytics Receives $1.7m Phase II SBIR Grant from the NIH to Advance its Rotator Cuff Muscle Analysis Technology

Retrieved on: 
Tuesday, March 5, 2024

"Springbok has the potential to significantly enhance how we understand, manage, and treat RC tears and improve surgical outcomes.

Key Points: 
  • "Springbok has the potential to significantly enhance how we understand, manage, and treat RC tears and improve surgical outcomes.
  • Springbok's technology overcomes these two challenges through the use of AI and innovative analysis methods, described in recent studies in Radiology: Artificial Intelligence and Scientific Reports .
  • Leveraging its proprietary muscle analytics, Springbok's AI technology produces an enhanced RC analysis from standard MRIs that are acquired within the clinical workflow.
  • "Phase I demonstrated implementation viability of our new analysis, proving it was both valuable and practical within the clinical setting.

Neurophet introduces AI-powered brain imaging analysis technology at AD/PD 2024

Retrieved on: 
Monday, March 4, 2024

SEOUL, South Korea, March 4, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announced its participation in the international conference on Alzheimer's and Parkinson's diseases and related neurological disorders (AD/PD 2024).

Key Points: 
  • At this conference, Neurophet will introduce Alzheimer's disease treatment related technologies planned to be commercialized such as analysis of the side effect and amyloid-positive prediction.
  • Neurophet AQUA analyzes brain atrophy and white matter hyperintensities (WMH) found in brain MRI of most Alzheimer's disease patients.
  • Neurophet SCALE PET provides quantitative regional amyloid beta deposition, known as the causative agent of Alzheimer's disease, using PET images.
  • Neurophet plans to launch total solution for Alzheimer's disease treatment including ARIA analysis, since Neurophet has the technology to analyze ARIA.

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, February 15, 2024

Our strong 2023 commercial results reflect that physicians are more regularly screening for hypercortisolism.

Key Points: 
  • Our strong 2023 commercial results reflect that physicians are more regularly screening for hypercortisolism.
  • Corcept’s fourth quarter 2023 revenue was $135.4 million, compared to $103.1 million in the fourth quarter of 2022.
  • Diluted net income per common share was $0.28 in the fourth quarter of 2023, compared to $0.14 in the fourth quarter of 2022.
  • Cash and investments were $425.4 million at December 31, 2023 compared to $436.6 million at December 31, 2022.

Mission Expanded - VIVE Focus 3 In Space Will Now Be Used For Physical Health

Retrieved on: 
Thursday, February 15, 2024

SEATTLE, Feb. 15, 2024 /PRNewswire/ -- Following The deployment of VIVE Focus 3 on the ISS for mental health was an incredible milestone -- Cher Wang, HTC Chairwomane successful deployment of HTC's VIVE Focus 3 onboard the International Space Station (ISS) to support with mental health, the mission has expanded to include physical health.

Key Points: 
  • SEATTLE, Feb. 15, 2024 /PRNewswire/ -- Following The deployment of VIVE Focus 3 on the ISS for mental health was an incredible milestone -- Cher Wang, HTC Chairwomane successful deployment of HTC's VIVE Focus 3 onboard the International Space Station (ISS) to support with mental health, the mission has expanded to include physical health.
  • The deployment of VIVE Focus 3 on the ISS for mental health was an incredible milestone -- Cher Wang, HTC Chairwoman
    Now the VIVE Focus 3 is being used as part of vital exercise routines.
  • Upon returning to Earth, some astronauts have spent up to 12 months in physical rehabilitation to regain full fitness.
  • While in space they must exercise for two hours every day just to try and minimise the effects of microgravity.